LLY
Eli Lilly and Company
LLY has the edge over MDLN overall, supported by stronger fundamentals and stronger modeled upside.
MDLN
Medline Inc.
MDLN trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Healthy | |
| Weak |
MDLN's profitability and cash flow are currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MDLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 33x | $22.09 | -45% |
| Fair | 40x | $27.00 | -32% |
| Expensive | 42x | $28.23 | -29% |
| Current | 60x | $39.98 | — |
Historical ranges are pointers, not guarantees.
MDLN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MDLN Forward outlook
There aren't enough analyst estimates for MDLN to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
MDLN Earnings Per Share
MDLN and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MDLN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MDLN on profitability, with a higher operating margin.
MDLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9B | +10% |
| Q2 2026 | $7.7B | +12% |
| Q1 2026 | $7.4B | +11% |
| Q3 2025 | $7.1B | +11% |
| Q2 2025 | $6.9B | +11% |
MDLN's revenue has grown year over year every quarter since late 2025: $7.9B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.4% | -1.7 points |
| Q2 2026 | 5.1% | -4 points |
| Q1 2026 | 5.7% | -3.2 points |
| Q4 2025 | 5.5% | N/A |
| Q3 2025 | 8.1% | -0.9 points |
| Q2 2025 | 9.1% | +0.8 points |
| Q1 2025 | 8.9% | N/A |
| Q3 2024 | 9% | N/A |
MDLN's operating margin was 6.4% last quarter, down 1.7 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
MDLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $884M | +65% |
| Q2 2026 | $604M | +486% |
| Q1 2026 | $316M | -41% |
| Q3 2025 | $535M | -13% |
MDLN has the edge over LLY in the latest year-over-year cash flow comparison.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MDLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MDLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +53% | +455M shares |
| 1 year | +67% | +529M shares |
MDLN has 1.3B diluted shares, up 67% from a year ago, despite $2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $2B |
| Q3 2025 | $18M |
| Q2 2025 | $3M |
| Q1 2025 | $18M |
| Q3 2024 | $3M |
MDLN spent $2B buying back its own shares over the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over MDLN on leverage, with a lower net debt burden relative to earnings.
MDLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.6x | Elevated |
MDLN's net debt is about 4.0 years of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MDLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.9 | Neutral |
| Stochastic | 53.6 | Neutral |
MDLN's weekly RSI is 57 (neutral) and its Stochastic is 54 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over MDLN on valuation relative to its sector.
MDLN PE vs Healthcare Sector
| Metric | MDLN | Sector median | Relative |
|---|---|---|---|
| PE | 60x | 26x | 131% above |
MDLN is trading at 60x earnings, a 131% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
MDLN has stronger trend alignment. LLY is above 5 of 5 weekly averages versus MDLN above 2 of 2.
MDLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.1 | 11% above |
| 20 week MA | $36.6 | 9.3% above |
MDLN is in an uptrend: it's above all two of its weekly moving averages, and 9.3% above its 20-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MDLN on returns for 2026, with the stronger performance.
MDLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $41.7 | $44.1 | +6% |
| 2026 YTD | $44.1 | $40.0 | -9.4% |
MDLN has finished every year since 2025 higher, and it's down 9.4% so far in 2026.